Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
benzodiazepine |
| gptkbp:activeIngredient |
gptkb:buspirone
|
| gptkbp:approvedBy |
1986 (US FDA)
|
| gptkbp:ATCCode |
N05BE01
|
| gptkbp:brand |
gptkb:Buspar
|
| gptkbp:CASNumber |
33386-08-2
|
| gptkbp:contraindication |
hypersensitivity to buspirone
|
| gptkbp:drugClass |
gptkb:azapirone
|
| gptkbp:eliminationHalfLife |
2-3 hours
|
| gptkbp:excretion |
renal
fecal |
| gptkbp:hasMolecularFormula |
C21H32ClN5O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
buspirone hydrochloride
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
serotonin 5-HT1A receptor partial agonist |
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness headache nervousness |
| gptkbp:usedFor |
treatment of generalized anxiety disorder
|
| gptkbp:bfsParent |
gptkb:buspirone
|
| gptkbp:bfsLayer |
7
|